Ogawa N
Department of Neuroscience, Medicine, Okayama University Medical School.
Nihon Rinsho. 1997 Jan;55(1):43-51.
Although levodopa is the most effective therapeutic agent for Parkinson's disease (PD) and has improved the QOL and increased the life expectancy of patients with PD, its beneficial effects are not permanent. Long-term levodopa therapy has many problems, including wearing-off, on-off phnonena, dyskinesia and psychotic symptoms, and has created serious problems for patients with PD. New therapeutic strategies are therefore needed to treat patients with PD. Given the well-known imbalance between dopaminergic and cholinergic activities in brain of PD patients, recent drug therapy has consisted of a multi-drug regimen, with low doses of levodopa, dopamine agonists, amantadine and anti-cholinergics. The most important is combination therapy with a dopamine agonist and low dose levodopa. This combination therapy is likely to create a better balance between postsynaptic D2- and D1-receptors and to maintain a normal dopamine neurotransmission for longer periods.
尽管左旋多巴是治疗帕金森病（PD）最有效的药物，改善了PD患者的生活质量并延长了其预期寿命，但其有益效果并非持久。长期左旋多巴治疗存在许多问题，包括疗效减退、开关现象、运动障碍和精神症状，给PD患者带来了严重问题。因此，需要新的治疗策略来治疗PD患者。鉴于PD患者大脑中多巴胺能和胆碱能活动之间众所周知的失衡，近期的药物治疗采用了多药联合方案，包括低剂量左旋多巴、多巴胺激动剂、金刚烷胺和抗胆碱能药物。最重要的是多巴胺激动剂与低剂量左旋多巴的联合治疗。这种联合治疗可能会在突触后D2和D1受体之间创造更好的平衡，并在更长时间内维持正常的多巴胺神经传递。
